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Abstract
Background: Randomized controlled trials (RCTs) that use the modified intention-to-treat (mITT) approach are
increasingly being published. Such trials have a preponderance of post-randomization exclusions, industry
sponsorship, and favourable findings, and little is known whether in terms of these items mITT trials are different
with respect to trials that report a standard intention-to-treat.
Methods: To determine differences in the methodological quality, sponsorship, authors’ conflicts of interest, and
findings among trials with different “types” of intention-to-treat, we undertook a cross-sectional study of RCTs
published in 2006 in three general medical journals (the Journal of the American Medical Association, the New
England Journal of Medicine and the Lancet) and three specialty journals (Antimicrobial Agents and
Chemotherapy, the American Heart Journal and the Journal of Clinical Oncology). Trials were categorized based on
the “type” of intention-to-treat reporting as follows: ITT, trials reporting the use of standard ITT approach; mITT,
trials reporting the use of a “modified intention-to-treat” approach; and “no ITT”, trials not reporting the use of any
intention-to-treat approach. Two pairs of reviewers independently extracted the data in duplicate. The strength of
the associations between the “type” of intention-to-treat reporting and the quality of reporting (sample size
calculation, flow-chart, lost to follow-up), the methodological quality of the trials (sequence generation, allocation
concealment, and blinding), the funding source, and the findings was determined. Odds ratios (OR) were
calculated with 95% confidence intervals (CI).
Results: Of the 367 RCTs included, 197 were classified as ITT, 56 as mITT, and 114 as “no ITT” trials. The quality of
reporting and the methodological quality of the mITT trials were similar to those of the ITT trials; however, the
mITT trials were more likely to report post-randomization exclusions (adjusted OR 3.43 [95%CI, 1.70 to 6.95]; P <
0.001). We found a strong association between trials classified as mITT and for-profit agency sponsorship (adjusted
OR 7.41 [95%CI, 3.14 to 17.48]; P < .001) as well as the presence of authors’ conflicts of interest (adjusted OR 5.14
[95%CI, 2.12 to 12.48]; P < .001). There was no association between mITT reporting and favourable results; in
general, however, trials with for-profit agency sponsorship were significantly associated with favourable results
(adjusted OR 2.30; [95%CI, 1.28 to 4.16]; P = 0.006).
Conclusion: We found that the mITT trials were significantly more likely to perform post-randomization exclusions
and were strongly associated with industry funding and authors’ conflicts of interest.
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The intention-to-treat principle requires that all partici-
pants that are randomized must be included in the final
analysis and analyzed according to the treatment group to
which they were originally assigned, regardless of the
treatment received, withdrawals, lost to follow-up or
cross-overs. Despite this principle, in many instances in
randomized trials the term intention-to-treat was inappro-
priately described and participants improperly excluded
[1-4]. In addition, the use of a modified intention-to-treat
(mITT) approach in randomized controlled trials (RCTs)
is increasingly appearing in the medical literature accord-
ing to a systematic review [5]. There is no clear definition
of what is mITT. In fact, descriptions of mITT analyses
vary greatly from trial to trial, and often contain more
than one criterion that are difficult to interpret as it is not
easy to discriminate between missing data cases and devia-
tions from protocol. Moreover, while post-randomization
exclusion appear to be the primary factor that charac-
terizes the mITT analysis, the majority of the trials were
industry sponsored and reported results that favoured the
therapy under investigation [5]. The uncertainty or equi-
poise principle that should exist in the design of RCTs
states that over time, the mean benefit of investigational
therapies and comparison therapies should be equal [6].
The high prevalence of significant results reported in ran-
domized trials might not reflect true differences [7]. Some
argue that this principle can be violated in the presence of
financial ties between investigators and the pharmaceutical
industry [8]. The biomedical literature reports strong and
consistent evidence that industry-sponsored research is
likely to produce pro-industry conclusions [9]. The
appearance of mITT reporting in modern RCTs could be
a consequence of the widespread financial ties that exists
among investigators and industry.
In this cross-sectional study, we examined whether
mITT reporting trials were different in terms of metho-
dological quality from trials with other types of inten-
tion-to-treat reporting. Our first hypothesis was that
studies using mITT analyses would be associated with
limited quality of reporting and study characteristics
based on the assumption that mITT reporting is a lim-
itation in principle. Moreover, we investigated whether
the reporting of mITT in RCTs was associated with
industry sponsorship, the presence of authors’ conflicts
of interest, and favourable findings.
Methods
Selection of Studies
To compare methodological quality, industry sponsor-
ship, the presence of authors’ conflicts of interest, and
findings among trials based on the type of intention-to-
treat reporting, we sought to identify the top medical
journals and specialty journals published in 2006 that
were more likely to report the use of an mITT approach
according to our previous survey [10]. The three high-
ranking medical journals were the Journal of American
Medical Association, the New England Journal of Medi-
cine and the Lancet; and the three specialty journals were
Antimicrobial Agents and Chemotherapy, the American
Heart Journal and the Journal of Clinical Oncology. We
carried out a computerized search in Medline (via
PubMed) to identify RCTs published in these six journals
using the publication type “randomized controlled trials”.
The results were then cross-checked against a search of
the Cochrane Central Register of Controlled Trials.
Excluded reports included: reports of phase I trials;
pharmacokinetic, pharmacodymanic or dose-comparing
studies; cluster RCTs; post-hoc studies; research letters;
cost-effectiveness studies; study protocols; and prognos-
tic and diagnostic studies. Two authors screened all of
the full-text journal articlest oc o n f i r mt h e i re l i g i b i l i t y
for inclusion and excluded 97 articles (Figure 1).
Two other reviewers independently and in duplicate,
extracted the following information from the journal
articles: characteristics of the trial, primary outcomes,
number of allocation groups, number of patients, main
outcome measure, P-values, and number of subjects
excluded from the analysis. Moreover, reporting of
f l o w - c h a r t s ,s a m p l es i z ec a l culations, and information
regarding missing data, withdrawals or patients lost to
follow-up were recorded.
The relevant RCTs were subsequently classified accord-
ing to the type of intention-to-treat analyses used as fol-
lows: ITT, trials reporting the use of standard ITT
analyses; mITT, trials reporting the use of “modified inten-
tion-to-treat” analyses; or “no ITT” trials not reporting the
use of any intention-to-treat analyses. This classification
was independent of the reporting of any post-randomisa-
tion exclusion. Trials reporting the use of ITT with
descriptions or conditions different from the standard
intention-to-treat definition were classified as mITT.
Descriptions of mITT were retrieved to evaluate the
type and deviation from a true intention-to-treat analy-
sis according to our previous classification [5].
Assessment of Methodological Quality
Sequence generation, allocation concealment and blind-
ing were used as indicators of methodological quality
and were classified as “adequate,”“ inadequate” or
“unclear.” In our analysis, the “inadequate” and “unclear”
categories were collapsed into “not adequate.” For
sequence generation, the following approaches were
considered adequate: random number table, computer
random number generator, drawing of lots and envel-
opes. The use of methods such as case record number,
d a t eo fb i r t ho rd a y ,m o n t h ,o ry e a ro fa d m i s s i o nw e r e
considered inadequate for sequence generation.
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coded drug packs prepared by an independent pharma-
cist and sequentially numbered, sealed and opaque
envelopes or any method that hindered the researchers’
ability to foresee the next assignment was considered
adequate. Methods such as procedures based on
inadequate generation of allocation sequences, open
allocation schedules, alternation and unsealed or non-
opaque envelopes were considered inadequate.
Regarding blinding, a trial was considered adequately
blinded if it was described as “double-blinded” and used
adequate methods such as identical placebo tablets or
464 potential randomized  trials 
published in 2006: 
JCO       117 
NEJM   114 
AHJ         87 
JAMA     57 
Lancet     55 
AAC        34 
97 Articles excluded with reasons: 
Pharmacodynamic or  
         Non-clinical studies              36 
Cluster RCTs                                 10 
Post-hoc studies                             12 
Prognostic or diagnostic studies    12 
Study protocols                              10 
Phase I                                             6 
Non-randomized studies                  4 
Research letters                                3 
Cost-effectiveness studies                2 
Reviews                                            2 
367 RCTs Included 
Figure 1 Study Screening Process. AAC: Antimicrobial Agents and Chemotherapy; AHJ: American Heart Journal; JAMA: Journal of American
Medical Association; JCO: Journal of Clinical Oncology; NEJM: New England Journal of Medicine.
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come assessor) in cases where blinding of participants
and caregivers may not be feasible. Each eligible trial
was independently reviewed for methodological quality.
Discrepancies were resolved by discussion, and a con-
sensus was reached for all trials.
Funding Source
Information regarding the sources of funding for each
trial was extracted from the articles by reviewing the
article text, the conflict of interest section, information
on funding (if present) and the acknowledgements
section. RTC funding sources were abstracted and cate-
gorized as follows: (1) not-for-profit organization;
(2) for-profit agency; (3) co-financed, indicating funding
from both not-for-profit organization(s) and for-profit
agency(s); (4) no funding; and (5) not reported.
Authors’ Potential Conflicts of Interest
The presence or absence of author conflicts of interest
was determined by reviewing the authors’ institutional
affiliations, the conflicts of interest section, information
on funding (if present) and the acknowledgements
section.
The institutional affiliation of the first author (e.g.,
university, not-for-profit organization or for-profit
agency) was retrieved from each article. The affiliation
of the other authors was also recorded when a financial
tie with a for-profit agency was present. Subsequently,
the studies were classified for analysis as follows: (1)
authors declaring no competing interests; (2) financial
ties with the sponsor of the study disclosed, indicating
that at least one author participated on behalf of a for-
profit agency (e.g., as an employee or consultant); (3)
other financial ties disclosed, indicating that an author
did not participate on behalf of the study sponsor but
did report a conflict of interest such as a past financial
tie with the pharmaceutical industry; and (4) conflicts of
interest not reported.
Study Findings
For each published trial, the results for each primary
outcome were classified as one of the following: (1)
favourable, if the result was statistically significant with
P < 0.05 or if the confidence interval did not include the
null; or (2) inconclusive, if the result did not reach sta-
tistical significance.
For equivalence or noninferiority studies, the result
was coded as favourable when the assumption of equiva-
lence or noninferiority was satisfied.
Statistical Methods
The distribution of various characteristics of the exam-
ined trials such as the type of ITT analysis and the
source of funding were reported using descriptive statis-
tics. The Pearson chi-square test was used for contin-
gency table analysis. Interobserver agreement was
measured using the kappa () statistic.
We investigated the associations between the “type” of
intention-to-treat analysis (as a dependent, multinomial
3-level variable: ITT, mITT, or “no ITT”) and the meth-
odological quality (sequence generation, allocation con-
cealment and blinding; Model A), the quality of
reporting (reporting of a flow-chart, sample size calcula-
tion, and lost to follow-up; Model A), the funding
source (Model B), and the presence of authors’ conflicts
of interest (Model C) using multinomial logistic
regression.
Bivariate analyses were performed to identify indepen-
dent variables with a P value less than or equal to 0.10.
These potential confounding variables were included in
each model of multivariate multinomial logistic regres-
sion analysis. In each model, the variables of journal
type, use of placebo, the presence of post-randomisation
exclusions, and all of the items used as indicators of
methodological quality and quality of reporting were
included. In model A, in addition to all the mentioned
variables, the use of funding was included (the inclusion
of the presence of authors’ conflict of interest instead of
funding did not produce any change in the results of
the model).
In each model, the ITT category was used as a refer-
ence for comparisons.
Furthermore, we performed univariate logistic regres-
sion to investigate the association between findings (as a
dependent variable) and the “type” of intention-to-treat
(as an independent polynomial 3-level variable: ITT,
mITT, “no ITT”). To account for potential confounding
variables we performed a multivariate logistic regression
and included in the model the type of the journal, the
use of placebo, the presence of post-randomisation
exclusions, the use of funding and all the items that
were indicators of reporting and methodological quality.
Finally, we assessed the overall association between
favourable findings and no for-profit sponsorship using
al o g i s t i cr e g r e s s i o n( u n i v a r iate and multivariate model
were used; all of the above mentioned variables includ-
ing the “type” of intention-to-treat were used for adjust-
ment). This was done to evaluate any consistency with
studies in the biomedical literature that report a strong
association between industry sponsorship and positive
findings. The Pearson goodness-of-fit test was used to
assess the overall fit of the models. Odds ratios (ORs)
were then computed with confidence intervals (CIs).
A two-tailed P-value less than 0.05 was considered
statistically significant. The analyses were performed
using STATA/SE, version 8.2 for Windows (StataCorp,
College Station, Texas).
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Characteristics of the Included Studies
Our final sample consisted of 367 published RCTs. Of
these, 197 were classified as ITT trials, 114 as “no ITT”
trials and 56 as mITT trials (analysis of number and
types of mITT deviations are reported in Appendix 1).
The number of participants included in each RCT
ranged from 10 to 160,921 (median, 368; interquartile
range 140-991). Trials classified as mITT were signifi-
cantly more likely to be published in general medical
journals, to report post-randomisation exclusions and to
use placebo as a comparator. A total of 258 (69%) trials
received complete or partial financial support from a
for-profit agency and 216 of the trials (60%) reported
results that favoured the treatment under investigation.
The characteristics of the included trials are shown in
Table 1.
The kappa value for generation sequence was 0.79
(95% CI 0.74 to 0.85), for allocation concealment 0.82
(95% CI 0.77 to 0.88); for blinding, 0.78 (95% CI 0.72 to
0.84); and for intention-to treat analysis, 0.90 (95% CI
0.89 to 0.92). The kappa value for funding source was
0.96 (95% CI 0.95 to 0.97); for authors’ conflict of inter-
est, 0.94 (95% CI 0.93 to 0.96); and for study findings,
0.93 (95% CI 0.93 to 0.95).
Characteristics of the Included Trials and the Type of
Intention-to-treat Reporting
Multinomial logistic regression analyses showed that the
mITT trials were more likely to have inadequate or
Table 1 Characteristics of Included Randomised Controlled Trials
Characteristics All trials Type of Intention-to-treat reporting N (%)
N = 367 ITT
197 (54)
mITT
56 (15)
’no ITT’
114 (31)
Journal
Medical journals 200 (55) 123 (62) 33 (59) 44 (38)
Specialty journals 167 (45) 74 (38) 23 (41) 70 (61)
Study design features
Phase II 13 (4) 7 (4) 1 (2) 5 (4)
Equivalence/Noninferiority 31 (8) 14 (7) 9 (13) 10 (9)
Sample size [median, (IQR)] 368
(140-991)
476
(200-1160)
426
(198-1093)
201
(81-620)
Trials with post-randomization exclusions 177 (48) 84 (43) 37 (66) 56 (49)
Proportion of post-randomization exclusions [median, (IQR)] 4
(1-11)
3
(1-11)
4
(1-10)
5
(3-12)
Placebo use 123 (34) 51 (26) 27 (48) 45 (40)
Reporting and Quality assessment
Flow chart 222 (60) 137 (70) 37 (66) 48 (42)
Reporting of sample size calculation 285 (78) 172 (87) 42 (79) 69 (61)
Reporting of lost to follow-up/withdrawal 211 (57) 127 (64) 35 (63) 49 (43)
Adequate sequence generation 167 (46) 108 (55) 21 (39) 38 (33)
Adequate allocation concealment 125 (34) 78 (40) 22 (39) 25 (22)
Adequate blinding 110 (30) 57 (29) 25 (45) 28 (25)
Funding
Not-for-profit organization 137 (37) 88 (45) 9 (16) 40 (35)
For-profit agency 121 (33) 52 (26) 40 (71) 32 (28)
Co-financed 66 (18) 42 (21) 5 (9) 19 (17)
Not reported 43 (12) 18 (9) 2 (4) 23 (20)
Author’s conflict of interest
Author declaring no competing interests 113 (31) 74 (38) 8 (14) 31 (27)
Author on behalf of a for-profit agency 143 (39) 70 (36) 40 (71) 33 (29)
Author disclosing other financial ties 61 (17) 42 (21) 3 (5) 16 (15)
No report of competing interests 50 (14) 11 (6) 5 (9) 34 (30)
Primary Outcome
Favorable to test drug 216 (60) 110 (56) 38 (70) 68 (60)
IQR = Inter-quartile range.
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compared to the ITT trials. Trials classified as “no ITT”
reported low standards of reporting and methodological
quality.
I nt h em u l t i v a r i a t ea n a l y s i s, the mITT trials appeared
to have substantially similar methodological quality stan-
dards compared to the ITT trials; however, the mITT
trials remained more likely to report post-randomisation
exclusions (adjusted OR 3.43 [95% CI 1.70 to 6.95]; P =
0.001). Trials classified as “no ITT” were significantly
more likely to avoid reporting flow-chart, sample size
calculation and lost to follow-up. Table 2 shows the
unadjusted and adjusted ORs of the strength of associa-
tion between characteristics of the studies and the type
of intention-to-treat reporting.
Sponsorship, Conflicts of Interest and the Type of
Intention-to-treat Reporting
Compared to the ITT trials, RCTs classified as mITT
were more likely to receive sponsorship from a for-profit
agency (adjusted OR 7.41 [95% CI 3.14 to 17.48]; P <
0.001) and were more likely to have at least one investi-
gator who was authoring on behalf of the pharmaceuti-
cal industry (adjusted OR 5.14 [95%CI, 2.12 to 12.48];
P < 0.001). Interestingly, both the mITT and “no ITT”
trials reported a higher odds ratio of authors not report-
ing any conflicts of interest. Table 3 shows the unad-
justed and adjusted ORs of the strength of association
between funding and authors’ conflicts of interest and
the type of intention-to-treat reporting.
Analysis of the Findings
We did not find any association between mITT report-
ing and favourable results (adjusted OR 1.27 [95% CI
0.62 to 2.61]; P = 0.51). Overall, however, trials with for-
profit agency sponsorship were more likely to report
favourable results when compared to trials that did not
receive any sponsorship from a for-profit agency
(adjusted OR 2.30 [95% CI 1.28 to 4.16]; P = 0.006).
Discussion
In a sample of RCTs, we assessed the associations
between the type of intention-to-treat analysis used and
study design characteristics, including the source of
funding and the favourability of the results. Our first
hypothesis that studies using mITT analyses would be
associated with limited quality of reporting and study
characteristics was refuted. Instead, we found that the
mITT trials were methodologically similar to the ITT
trials.
Reports from the literature about the methodological
quality of industry sponsored trials are controversial.
While some authors report that the methodological
quality of industry-sponsored RCTs is limited, others
report that trials funded by for-profit agencies have
similar or better methodological quality than unsup-
ported trials [8,11].
In our investigation, the mITT trials were more likely
to perform post-randomisation exclusions compared to
both ITT trials and “no ITT” trials. A study published
in 1996 reported a paradox that RCTs reporting ITT
Table 2 Association Between Characteristics of the Included Randomised Controlled Trials and the Type of Intention-
to-treat Reporting
Type of
Intention-
to-treat
Journal
Medical
vs.
specialty
Placebo
Non-
placebo vs.
placebo
Post-
randomization
exclusion
Reported vs.
not reported
Flow chart
Not
reported vs.
reported
Sample size
calculation
Not
reported vs.
reported
Lost to
follow-up
Not
reported vs.
reported
Sequence
Generation
Not
adequate vs.
adequate
Allocation
concealment
Not
adequate vs.
adequate
Blinding
Not
adequate vs.
adequate
Unadjusted Odds Ratio (Confidence Interval 95%)
mITT 1.16
(0.63 to
2.12)
2.67
(1.44 to
4.92)
2.62
(1.41 to 4.88)
1.17
(0.62 to 2.20)
1.87
(0.87 to 4.02)
1.09
(0.59 to 2.01)
1.42
(1.05 to 1.93)
1.01
(0.74 to 1.36)
0.50
(0.27 to 0.93)
“no ITT” 2.64
(1.64 to
4.25)
1.87
(1.14 to
3.05)
1.30
(0.82 to 2.06)
3.14
(1.94 to 5.07)
4.47
(2.55 to 7.88)
2.41
(1.50 to 3.86)
1.52
(1.23 to 1.98)
1.53
(1.17 to 1.99)
1.25
(0.74 to 2.12)
Adjusted Odds Ratio (Confidence Interval 95%)
mITT 1.43
(0.61 to
3.35)
2.85
(1.22 to
6.63)
3.43
(1.70 to 6.95)
1.05
(0.47 to 2.37)
3.24
(1.32 to 7.98)
1.13
(0.54 to 2.36)
1.15
(0.79 to 1.69)
0.98
(0.69 to 1.41)
1.00
(0.43 to 2.34)
“no ITT” 1.87
(0.94 to
3.69)
4.11
(2.02 to
8.36)
2.27
(1.30 to 3.93)
1.92
(1.03 to 3.55)
4.05
(2.10 to 7.84)
2.09
(1.20 to 3.66)
1.06
(0.79 to 1.43)
1.24
(0.91 to 1.69)
1.88
(0.90 to 3.94)
ITT is the comparison group.
mITT = modified intention-to-treat.
ITT = intention-to-treat.
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perform exclusions [12]. The authors’ interpretation of
this finding was that studies with low methodological
standards may be less likely to report exclusions, even
when exclusions actually occurred. In our analysis,
although the mITT trials had the highest occurrence of
exclusions, we found that the “no ITT” trials were more
likely to perform exclusions compared to the ITT trials.
It is possible that the standard of reporting changed
over time, and we can speculate that allowing any modi-
fication of the standard intention-to-treat analysis may
have encouraged authors to report exclusions after
deciding which “type” of mITT analysis to perform.
Several studies in the medical literature report that
post-randomisation exclusions in randomised trials may
lead to biased estimates of the treatment effect. Indivi-
dual patient data analyses of systematic reviews found
that the results were in favor to the treatment under
investigation when exclusions were not taken into
account in the results rather than when a true intention-
to-treat was used [13]. A meta-epidemiological study that
investigated 14 meta-analyses in osteoarthritis showed
that the exclusion of patients from analysis resulted in a
biased estimate of the treatment effect [14]. Another
study of pharmaceutical industry sponsored trials investi-
gating serotonin reuptake inhibitors found that results
were more in favour when a per-protocol analysis was
used instead of intention-to-treat analysis [15].
The second aim of our study was to assess the associa-
tions between the type of intention-to-treat analysis used
and the presence of industry sponsorship or author con-
flicts of interest among RCTs. In the RCTs included in
this study the use of mITT analysis was strongly associated
with industry funding and author conflicts of interest.
In the medical literature, the r ei sp l e n t yo fe v i d e n c e
that the pharmaceutical industry is directly or indirectly
involved at different stages in the conduct, design and
publication of biomedical research [9,11,16]. The selec-
tion of an inappropriate comparison group (e.g., a drug
with non-equivalent dosage) [8,17,18], multiple report-
ing of studies [19,20] and suppression or delay of publi-
cations [18] are all circumstances where the presence of
industry sponsorship are well documented.
We did not find any association between favourable
results and mITT reporting. The number of mITT trials
was too low to detect any difference; however, even if
the sample of trials was adequate, we are aware that any
potential difference cannot be free of bias given the
large heterogeneity of the included trials in terms of the
intervention and outcome investigated. We believe,
nonetheless, that the appropriate place to evaluate the
mITT as a source of bias is to explore its impact in
meta-epidemiological studies.
In our previous survey, we showed that publications of
mITT reporting trials is significantly increasing. For
example, the overall incidence of trials published in
2006 in the medical literature was around 5% [5]. This
incidence of mITT reporting trials was underestimated
since the studies claiming the use of the intention-to-
treat approach when in fact they used the mITT
Table 3 Association Between Funding and Authors’ Conflicts of Interest for the Included Randomised Controlled Trials
and the Type of Intention-to-treat Reporting
Type of
Intention-
to-treat
Funding Authors’ Conflicts of Interest
Not for-
profit
organization
For-
Profit
Agency
Co-
financed
Not
Reported
Author declaring
no competing
interests
Author on behalf
of a for-profit
agency
Author disclosing
other financial
ties
No report of
competing
interests
Unadjusted Odds Ratio (Confidence Interval 95%)
mITT 1 7.99
(3.59 to
17.82)
1.16
(0.37 to
3.69)
1.09
(0.22 to
5.46)
1 5.29
(2.31 to 12.08)
0.66
(0.16 to 2.63)
4.20
(1.16 to 15.19)
“no ITT” 1 1.44 0.99 2.81 1 1.12 0.91 7.38
(0.80 to
2.57)
(0.52 to
1.92)
(1.37 to
5.78)
(0.62 to 2.03) (0.45 to 1.85) (3.32 to 16.40)
Adjusted Odds Ratio (Confidence Interval 95%)
mITT 1 7.41
(3.14 to
17.48)
1.08
(0.32 to
3.58)
0.87
(0.16 to
4.71)
1 5.14
(2.12 to 12.48)
0.62
(0.15 to 2.61)
4.78
(1.03 to 22.08)
“no ITT” 1 1.23
(0.62 to
2.43)
0.82
(0.39 to
1.72)
1.31
(0.54 to
3.15)
1 0.88
(0.45 to 1.73)
0.60
(0.26 to 1.38)
3.77
(1.30 to 10.94)
ITT is the comparison group.
mITT = modified intention-to-treat.
ITT = intention-to-treat.
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description of the analysis) may have escaped the pre-
vious search [5]. Indeed, in the present study, we were
able to assess all the randomized trials in 6 journals,
and capture those trials that reported intention-to-treat
but with deviations. The number of these trials (n = 32)
was greater than the number of the trials that actually
reported as “modified” (n = 24; Box). Consequently, we
can conclude that the phenomenon of mITT is wider
than previously estimated.
Limitations
Our main limitation was that we used data from RCTs
that were published in six journals; therefore, we are
unsure that our results can be generalized to other trials
published elsewhere. To test our aforementioned
hypothesis, we needed to compare mITT trials with
trials reporting (or not reporting) intention-to-treat.
Although our previous research has documented an
increasing incidence of mITT trials, the proportion of
mITT trials being conducted remains too low to obtain
an adequate sample for comparison. Consequently, we
decided to target journals that were more likely to
report mITT trials by selecting general medical and spe-
cialty journals.
Conclusion
Data analysis is the crucial final stage of any study
design. Well-designed RCTs require strict adherence to
the intention-to-treat principle, in which subjects should
remain in the group to which they were originally allo-
cated. Although further research is needed to document
that the mITT is a potential source of bias, to limit
unjustified exclusions, the misuse of “intention-to-treat”
terminology should be abandoned, and authors need to
adhere to the standard intention-to-treat principle. The
updated version of the CONSORT statement goes into
this direction and suggests the replacement of any kind
of intention-to-treat reporting with a clear description
of exactly who was included in each analysis [21].
Appendix 1
Analyses of Types and Deviations from Intention-to-
Treat of Trials classified as mITT
Of the 56 trials classified as mITT, 24 were reported
explicitly as “modified” while 32 reported “intention-to-
treat” but reported descriptions that deviate from the
true ITT and thus were considered as mITT trials.
Overall, 31 (55%) trials reported 1 type of mITT devia-
tion, 17 (30%) reported 2 types of mITT deviation, 5 (9%)
reported 3 types of mITT deviation, and 3 (5%) did not
report any type of mITT deviation. In 35 (63%) trials, the
main exclusion criterion for the mITT analysis was treat-
ment-related; in 18 of such trials, the treatment-related
mITT was accompanied by at least one additional type of
mITT deviation.
In 17 (30%) trials, the exclusion criteria used to justify
the mITT criteria was the absence of a post-baseline
assessment; in 13 of these trials, it was accompanied by
at least one other type of mITT deviation.
Baseline assessment related mITT was described in 10
(18%) trials; in 6 of these the approach was accompanied
by another type of deviation. Four (7%) trials required a
target condition to describe the mITT deviation; and 1
(2%) trial fell into the follow-up related mITT deviation.
While 13 (23%) trials did not fall into none of the above
category, 3 (5%) trials remained without any type of
mITT description.
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